PURA VIDA INVESTMENTS, LLC - Q4 2019 holdings

Add to watchlist

$1.14 Billion is the total value of PURA VIDA INVESTMENTS, LLC's 100 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 77.4% .

All

			Value		Shares		↓ Weighting
ESTA	Sell	ESTABLISHMENT LABS HLDGS INC	$18,881,000	+34.0%	682,600	-8.4%	1.66%	-31.0%
NSTG	Sell	NANOSTRING TECHNOLOGIES INCcall	$18,194,000	+18.7%	654,000	-7.9%	1.60%	-38.9%
XENT	Sell	INTERSECT ENT INCcall	$16,285,000	+23.5%	654,000	-15.6%	1.43%	-36.4%
INSP	Sell	INSPIRE MED SYS INCcall	$12,096,000	-27.9%	163,000	-40.7%	1.06%	-62.9%
ZBH	Sell	ZIMMER BIOMET HLDGS INCcall	$9,879,000	-28.0%	66,000	-34.0%	0.87%	-62.9%
TXG	Sell	10X GENOMICS INC	$6,660,000	+46.8%	87,340	-3.0%	0.59%	-24.4%
CNMD	Sell	CONMED CORP	$5,181,000	+13.4%	46,330	-2.5%	0.46%	-41.5%
TGTX	Sell	TG THERAPEUTICS INC	$3,082,000	+54.7%	277,639	-21.7%	0.27%	-20.3%
RCM	Sell	R1 RCM INCcall	$2,116,000	-32.3%	163,000	-53.4%	0.19%	-65.2%
INOV	Sell	INOVALON HLDGS INCcall	$2,051,000	-58.3%	109,000	-63.7%	0.18%	-78.6%
GNLN	Sell	GREENLANE HLDGS INCcl a	$1,787,000	-56.7%	549,017	-54.9%	0.16%	-77.7%
AVDL	Sell	AVADEL PHARMACEUTICALS PLCsponsored adr	$823,000	+63.0%	109,000	-10.2%	0.07%	-16.3%
ALRN	Exit	AILERON THERAPEUTICS INC	$0	–	-135,548	-100.0%	-0.02%	–
ADVM	Exit	ADVERUM BIOTECHNOLOGIES INC	$0	–	-100,000	-100.0%	-0.09%	–
ENDP	Exit	ENDO INTL PLCcall	$0	–	-200,000	-100.0%	-0.11%	–
ITCI	Exit	INTRA CELLULAR THERAPIES INC	$0	–	-109,130	-100.0%	-0.14%	–
CHRS	Exit	COHERUS BIOSCIENCES INC	$0	–	-50,000	-100.0%	-0.17%	–
AXSM	Exit	AXSOME THERAPEUTICS INC	$0	–	-58,519	-100.0%	-0.20%	–
ZYME	Exit	ZYMEWORKS INC	$0	–	-50,000	-100.0%	-0.21%	–
STML	Exit	STEMLINE THERAPEUTICS INC	$0	–	-132,422	-100.0%	-0.24%	–
ARVN	Exit	ARVINAS INC	$0	–	-64,209	-100.0%	-0.24%	–
FLDM	Exit	FLUIDIGM CORP DELcall	$0	–	-300,000	-100.0%	-0.24%	–
DCPH	Exit	DECIPHERA PHARMACEUTICALS IN	$0	–	-41,000	-100.0%	-0.24%	–
SAGE	Exit	SAGE THERAPEUTICS INCcall	$0	–	-10,000	-100.0%	-0.24%	–
BHVN	Exit	BIOHAVEN PHARMACTL HLDG CO L	$0	–	-40,000	-100.0%	-0.28%	–
CMD	Exit	CANTEL MED CORPput	$0	–	-25,000	-100.0%	-0.32%	–
MSON	Exit	MISONIX INC	$0	–	-93,645	-100.0%	-0.32%	–
ACHN	Exit	ACHILLION PHARMACEUTICALS IN	$0	–	-566,600	-100.0%	-0.35%	–
CYTK	Exit	CYTOKINETICS INC	$0	–	-188,096	-100.0%	-0.37%	–
BDSI	Exit	BIODELIVERY SCIENCES INTL IN	$0	–	-515,111	-100.0%	-0.37%	–
TNDM	Exit	TANDEM DIABETES CARE INC	$0	–	-40,000	-100.0%	-0.40%	–
CSTL	Exit	CASTLE BIOSCIENCES INC	$0	–	-131,718	-100.0%	-0.41%	–
SUPN	Exit	SUPERNUS PHARMACEUTICALS INCput	$0	–	-100,000	-100.0%	-0.47%	–
IVC	Exit	INVACARE CORPcall	$0	–	-400,000	-100.0%	-0.51%	–
WMGI	Exit	WRIGHT MED GROUP N Vcall	$0	–	-150,000	-100.0%	-0.53%	–
UTHR	Exit	UNITED THERAPEUTICS CORP DEL	$0	–	-39,000	-100.0%	-0.53%	–
GWPH	Exit	GW PHARMACEUTICALS PLCads	$0	–	-30,000	-100.0%	-0.59%	–
MRTX	Exit	MIRATI THERAPEUTICS INCcall	$0	–	-50,000	-100.0%	-0.67%	–
SPPI	Exit	SPECTRUM PHARMACEUTICALS INCput	$0	–	-500,000	-100.0%	-0.71%	–
MDCO	Exit	MEDICINES COcall	$0	–	-100,000	-100.0%	-0.85%	–
BAX	Exit	BAXTER INTL INC	$0	–	-60,000	-100.0%	-0.90%	–
STAA	Exit	STAAR SURGICAL COcall	$0	–	-231,200	-100.0%	-1.02%	–
VRAY	Exit	VIEWRAY INCcall	$0	–	-2,250,000	-100.0%	-1.12%	–
CHRS	Exit	COHERUS BIOSCIENCES INCcall	$0	–	-400,000	-100.0%	-1.38%	–
SNN	Exit	SMITH & NEPHEW GROUP PLCspdn adr new	$0	–	-180,000	-100.0%	-1.48%	–
GILD	Exit	GILEAD SCIENCES INC	$0	–	-150,000	-100.0%	-1.62%	–
IBB	Exit	ISHARES TRcall	$0	–	-109,200	-100.0%	-1.86%	–
REGN	Exit	REGENERON PHARMACEUTICALS	$0	–	-40,000	-100.0%	-1.90%	–
WAT	Exit	WATERS CORPcall	$0	–	-50,000	-100.0%	-1.91%	–
SNN	Exit	SMITH & NEPHEW GROUP PLCcall	$0	–	-265,000	-100.0%	-2.18%	–
REGN	Exit	REGENERON PHARMACEUTICALScall	$0	–	-50,000	-100.0%	-2.37%	–
MJ	Exit	ETF MANAGERS TRput	$0	–	-700,000	-100.0%	-2.48%	–
AMGN	Exit	AMGEN INCcall	$0	–	-100,000	-100.0%	-3.31%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR/A filed 2021-02-12

Signatures

The EDGAR filing(s) were signed by:

Alyssa Romano — Chief Compliance Officer and Chief Financial Officer

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
ICU MED INC	26	Q2 2023	4.2%
NANOSTRING TECHNOLOGIES INC	26	Q2 2023	3.3%
VIEWRAY INC	25	Q2 2023	3.2%
LIVANOVA PLC	23	Q3 2023	3.8%
ALEXION PHARMACEUTICALS INC	23	Q1 2021	4.3%
INSPIRE MED SYS INC	22	Q3 2023	3.7%
BOSTON SCIENTIFIC CORP	22	Q3 2022	4.8%
INVACARE CORP	22	Q3 2021	2.8%
ESTABLISHMENT LABS HLDGS INC	21	Q3 2023	5.0%
INTERSECT ENT INC	21	Q2 2021	2.6%

View PURA VIDA INVESTMENTS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)

PURA VIDA INVESTMENTS, LLC Q4 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
Stryve Foods Holdings, LLC	April 19, 2023	1,470,649	5.6%
ICAD INC	March 15, 2023	1,277,214	5.0%
ESTABLISHMENT LABS HOLDINGS INC.	February 14, 2023	1,002,767	4.1%
Pulmonx Corp	February 14, 2023	1,216,258	3.2%
Quotient Ltd^{Sold out}	February 14, 2023	0	0.0%
Universe Pharmaceuticals INC^{Sold out}	February 14, 2023	0	0.0%
MedMen Enterprises, Inc.	April 29, 2022	139,755,072	21.4%
INVACARE CORP^{Sold out}	February 14, 2022	0	0.0%
MedAvail Holdings, Inc.	February 14, 2022	714,120	2.2%
TELA Bio, Inc.	February 14, 2022	564,120	3.9%

View PURA VIDA INVESTMENTS, LLC's complete significant-ownership history.

Latest filings

Type	Filed
13F-HR	2024-05-15
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
13F-HR	2024-02-13

View PURA VIDA INVESTMENTS, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

The reported total value is incorrect (1136740000.0 != 1136744000.0)
The reported has been restated
The reported has been amended

Export PURA VIDA INVESTMENTS, LLC's holdings